Literature DB >> 2454114

Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.

M Kubota1, T Takimoto, A Tanizawa, Y Akiyama, H Mikawa.   

Abstract

The ability of hydroxyurea (HU) to modulate 1-beta-D-arabinofuranosylcytosine (Ara-C) metabolism was investigated in human leukemic cell lines. Exposure of HL-60 cells to 1 mM HU enhanced the accumulation of Ara-CTP up to 2.5-fold, whereas HU did not have significant effects on Ara-C metabolism in CEM cells. In addition, two adenine nucleosides, deoxyadenosine (dAdo) and 9-beta-D-arabinofuranosyladenine (Ara-A), which are known to be activated by deoxycytidine (dCyd) kinase as Ara-C, were more effectively phosphorylated after the addition of HU only in HL-60 cells. However, the changes of intracellular dCTP and TTP pools induced by HU, i.e. decrease in dCTP and increase in TTP, were the same in both cell lines. Finally, dCyd production under normal culture conditions was at least 3- to 4-fold higher in HL-60 cells and was inhibited significantly by HU administration. These results suggest that the modulation of Ara-C metabolism by HU occurs at the level of dCyd kinase through the regulation of de novo dCyd generation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454114     DOI: 10.1016/0006-2952(88)90438-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Increase in Ara-C sensitivity in Ara-C sensitive and -resistant leukemia by stimulation of the salvage and inhibition of the de novo pathway.

Authors:  L P Colly; D J Richel; M W Arentsen-Honders; M G Kester; P M ter Riet; R Willemze
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

Review 2.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

3.  A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.

Authors:  Amir Mortazavi; Yonghua Ling; Ludmila Katherine Martin; Lai Wei; Mitch A Phelps; Zhongfa Liu; Erica J Harper; S Percy Ivy; Xin Wu; Bing-Sen Zhou; Xiyong Liu; Deidre Deam; J Paul Monk; William J Hicks; Yun Yen; Gregory A Otterson; Michael R Grever; Tanios Bekaii-Saab
Journal:  Invest New Drugs       Date:  2012-07-31       Impact factor: 3.850

4.  Metabolism and toxicity of electroporated 1-beta-D-arabinofuranosylcytosine triphosphate in a human leukemia cell line.

Authors:  M Kubota; T Yorifuji; H Hashimoto; T Shimizu; H Mikawa
Journal:  Jpn J Cancer Res       Date:  1990-12

5.  Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Authors:  Sean G Rudd; Nikolaos Tsesmetzis; Kumar Sanjiv; Cynthia Bj Paulin; Lakshmi Sandhow; Juliane Kutzner; Ida Hed Myrberg; Sarah S Bunten; Hanna Axelsson; Si Min Zhang; Azita Rasti; Petri Mäkelä; Si'Ana A Coggins; Sijia Tao; Sharda Suman; Rui M Branca; Georgios Mermelekas; Elisée Wiita; Sun Lee; Julian Walfridsson; Raymond F Schinazi; Baek Kim; Janne Lehtiö; Georgios Z Rassidakis; Katja Pokrovskaja Tamm; Ulrika Warpman-Berglund; Mats Heyman; Dan Grandér; Sören Lehmann; Thomas Lundbäck; Hong Qian; Jan-Inge Henter; Torsten Schaller; Thomas Helleday; Nikolas Herold
Journal:  EMBO Mol Med       Date:  2020-01-17       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.